Top Causes of Death in Spain
Although death rates due to cardiovascular diseases in Spain are among the lowest in the EU, they represent the main cause of death in Spain, accounting for 30% of all…
Spain’s Richest Man is Moving Into Healthcare
The global rich list is splattered with household names who have built their reputation not only through business acumen but through eye-catching purchases such as Steve Balmer’s record buyout of…
Top Causes of Death in France
Cancer is the leading cause of death in France, accounting for 28.5% of all deaths in 2014, followed by cardiovascular diseases, which accounted for 25%. However, there are gender differences:…
Spain’s Top Three Regional Healthcare Systems
One of the unique aspects of the system is the fragmentation linked to the country’s 17 autonomous regions The Spanish healthcare system performance is ranked as 7th in the world…
Sanofi growth returns thanks to Dupixent and revitalised vaccine sales
Oliver Brandicourt, Sanofi’s CEO has kept his promise to steer the company back on the path to growth. This change in fortune comes after the French Pharma giant suffered losses…
Brexit: A Window of Opportunity for France’s Drug Regulator?
As the UK prepares to leave the European Union in March 2019, stakeholders across the European life sciences industry are busy preparing for Brexit’s potential impact on their operations. In…
New Special Report on Pharma in Cyprus
With a population of just 1.2 million and a proportionately small pharmaceutical market by EU standards, Cyprus is often overlooked as a healthcare and life sciences investment destination. However, with…
Behind the Highest Life Expectancy in Europe
Madrid, Spain’s capital, is the city with the highest life expectancy in Europe at 85.2 years. Moreover, Spain as a whole is one of Europe’s best performers in terms of…
Advent of the Liquid Hospital
Spanish stakeholders have been trailblazing the concept of the “liquid hospital”, which envisions the virtual and physical expansion of healthcare provision beyond the parameters of the traditional centralized hospital structure.…
Artificial IntelliFrance
France is attempting to reposition itself as a globally competitive hub for artificial intelligence R&D, with significant state investment aiming to turn Paris into the next Palo Alto. With rapid…
M&A by necessity: Takeda and Shire
The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined…
Thomas Cueni on pricing and developing markets
In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models,…